|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's range||150.83 - 152.76|
|52-week range||150.11 - 186.69|
|Beta (5Y monthly)||0.54|
|PE ratio (TTM)||26.97|
|Earnings date||18 Apr 2023|
|Forward dividend & yield||4.52 (2.80%)|
|Ex-dividend date||17 Feb 2023|
|1y target est||183.63|
AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. After all, these stocks offer a track record of earnings growth and dividend increases. The company's mega-blockbuster immunology drug, Humira, recently started facing competition in the U.S. And AbbVie predicts that this will result in a 37% decline in the drug's sales this year.
It’s not just TikTok as a company that has a lot at stake right now. The people who are on TikTok the most, the influencers — also called creators — are also in the crosshairs.
While a volatile market continues to keep some investors on the sidelines, if you're putting your money into wonderful businesses in both good times and bad, you can prime your portfolio for more consistent returns over the long term. Johnson & Johnson (NYSE: JNJ) has a lengthy history of delivering returns to shareholders over a wide range of markets and economic environments through its faithful dividend payments. The last five years alone have seen J&J's dividend jump by more than 25%.